<?xml version="1.0" encoding="UTF-8"?>
<p>Although a favorable outcome has been shown in this study, the current recommendation of the Brazilian Society of Rheumatology for patients using bDMARDs with clinical-epidemiological or laboratory diagnosis of arbovirus infection is to suspend biological therapy until recovery from the acute phase of the disease [
 <xref rid="B21" ref-type="bibr">21</xref>].
</p>
